Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update GlobeNewswire May 13, 2025 – Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill(R) capsule, to subcutaneous administration of PG-102 – – Phase 1 study for RT-114 for the treatment of obesity expected to […]

CNB Financial Corporation Announces Quarterly Dividend for Common Stock

CNB Financial Corporation Announces Quarterly Dividend for Common Stock GlobeNewswire May 13, 2025 CLEARFIELD, Pa., May 13, 2025 (GLOBE NEWSWIRE) — The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) declared a quarterly cash dividend of $0.18 per share of common stock payable on June 13, 2025 to common stock shareholders of record as

NeuroPace Reports First Quarter 2025 Financial Results

NeuroPace Reports First Quarter 2025 Financial Results GlobeNewswire May 13, 2025 — Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products — — Increased full-year 2025 revenue guidance to $93 to $97 million — — On track to announce topline data from the NAUTILUS

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire May 13, 2025 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock

Arteris Announces Financial Results for the First Quarter and Estimated Second Quarter and Updated Full Year 2025 Guidance

Arteris Announces Financial Results for the First Quarter and Estimated Second Quarter and Updated Full Year 2025 Guidance GlobeNewswire May 13, 2025 CAMPBELL, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, today announced financial results for the first quarter ended March

Parsons Selected As Delivery Partner For King Salman International Airport

Parsons Selected As Delivery Partner For King Salman International Airport GlobeNewswire May 13, 2025 CHANTILLY, Va., May 13, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today, on the sidelines of the Saudi-US Investment Forum in Riyadh, that the company has been awarded two Delivery Partner (DP) contracts by the King Salman International Airport

Glass House Brands Reports First Quarter 2025 Financial Results

Glass House Brands Reports First Quarter 2025 Financial Results GlobeNewswire May 13, 2025 Wholesale biomass production was 152,568 pounds, up 149% year-over-year Cost of production was $108 per pound, a substantial improvement compared to $182 per pound in Q1 2024 First quarter 2025 revenue was $44.8 million, up 49% year-over-year and reflecting a 78% increase

Spectral AI Announces 2025 First Quarter Financial Results

Spectral AI Announces 2025 First Quarter Financial Results GlobeNewswire May 13, 2025 Q1 Overview Research & Development Revenue of $6.7 Million Improved Capital Structure Reflected in Cash of $14.1 Million Continued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May 13, 2025 (GLOBE NEWSWIRE) — Spectral AI,

Reed’s Reports First Quarter 2025 Results

Reed's Reports First Quarter 2025 Results Management to Host Conference Call Tomorrow at 8:30 a.m. ET GlobeNewswire May 13, 2025 NORWALK, Conn., May 13, 2025 (GLOBE NEWSWIRE) — Reed's, Inc. (OTCQX: REED) (“Reed's” or the “Company”), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three months

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire May 13, 2025 Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025 Recently completed

Scroll to Top